Literature DB >> 12395371

Skeletal muscle vasculitis exclusive of inflammatory myopathic conditions: a clinicopathologic study of 40 patients.

Richard A Prayson1.   

Abstract

Vasculitis is an infrequently encountered pathology in skeletal muscle biopsy specimens, the diagnosis of which has significant therapeutic implications. This study retrospectively reviewed the clinicopathologic features of 40 patients with vasculitis (infiltration of vessel walls by inflammatory cells) diagnosed via skeletal muscle biopsy during a 27-year period of time. Cases of vasculitis associated with inflammatory myopathic conditions, such as polymyositis or dermatomyositis, were excluded from study. Forty patients, including 21 women and 19 men ranging in age from 19 to 83 years (mean of 52 years), formed the study group. The most common clinical presentations included muscle pain (n = 22, 55%), paresthesias (n = 16, 40%), and weight loss (n = 15, 38%). Westergren erythrocyte sedimentation rate was known in 31 patients and ranged from 12 to >150 mm/h (mean, 61 mm/h). Necrotizing vasculitis was identified in 35 patients (88%). The vasculitic process involved multiple vessels in 30 cases (75%). Vessel wall scarring and/or fibrosis were identified in 11 patients (28%), thrombi in 3 patients (8%), eosinophils in 2 patients (5%), and granulomas in 1 patient (3%). Neurogenic changes were observed in the majority of biopsy specimens as follows: angular atrophic esterase-positive muscle fibers (n = 35, 88%), grouped atrophy (n = 14, 35%), fiber type grouping (n = 17, 43%), and target fibers (n = 6, 15%). Other commonly identified pathologies included scattered degenerating muscle fibers (n = 15, 38%), regenerating muscle fibers (n = 17, 43%), and type II muscle fiber atrophy (n = 10, 25%). Thirty-three patients also underwent sural nerve biopsy. Vasculitis was identified in the nerve in 26 of 33 of these patients (79%). Peripheral nerve vasculitis was classified as necrotizing in 15 cases (57.7%) and as nonnecrotizing in 11 cases (42.5%). Seventeen of 33 patients (52%) with known follow-up showed clinical improvement with steroid/immunosuppressive therapy. The following 2 conclusions were made: the majority of vasculitis cases arising outside the setting of inflammatory myopathy in skeletal muscle are necrotizing, and the predominant muscle pathology in the setting of vasculitis is neurogenic atrophy, likely caused by concomitant involvement of the peripheral nervous system. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Year:  2002        PMID: 12395371     DOI: 10.1053/hupa.2002.127443

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  6 in total

1.  [Differential diagnosis of a vasculitic syndrome of the lower limb].

Authors:  Nikolas Ruffer; Martin Krusche; Marie-Therese Holzer; Christian Hagel; Ina Kötter
Journal:  Z Rheumatol       Date:  2021-07-09       Impact factor: 1.372

2.  Necrosis of the gastrocnemius muscle in microscopic polyangiitis.

Authors:  Takahiko Akagi; Hirotake Nishimura; Tomoyuki Mukai; Yoshitaka Morita
Journal:  BMJ Case Rep       Date:  2018-01-26

3.  Three cases of primary small vessel vasculitis of the skeletal muscle-an own entity.

Authors:  Nadja Benz; Thomas Daikeler; Stephan Frank; Matthias Mehling; Alan Tyndall; Marten Trendelenburg
Journal:  BMJ Case Rep       Date:  2011-11-08

Review 4.  The utility of muscle biopsy.

Authors:  David Lacomis
Journal:  Curr Neurol Neurosci Rep       Date:  2004-01       Impact factor: 5.081

5.  Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis (AAV) Restricted to the Limbs.

Authors:  Yoshie Ojima; Kinya Sawada; Hiroshi Fujii; Tsuyoshi Shirai; Ayako Saito; Saeko Kagaya; Satoshi Aoki; Yoichi Takeuchi; Tomonori Ishii; Tasuku Nagasawa
Journal:  Intern Med       Date:  2017-12-27       Impact factor: 1.271

6.  The use of nerve and muscle biopsy in the diagnosis of vasculitis: a 5 year retrospective study.

Authors:  D L H Bennett; M Groves; J Blake; J L Holton; R H M King; R W Orrell; L Ginsberg; M M Reilly
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-09-26       Impact factor: 13.654

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.